Clinical Report: Hybrid Artificial Intelligence for Personalized Dose Recommendations

Overview

This study presents CGH-AI, a hybrid artificial intelligence framework designed to optimize dose recommendations and predict local control outcomes for patients with recurrent glioblastoma undergoing Gamma Knife radiosurgery. The model demonstrated strong internal validation performance, suggesting its potential to enhance personalized treatment planning.

Background

Recurrent glioblastoma poses significant challenges in neuro-oncology, with treatment outcomes varying widely among patients. Effective dose selection for Gamma Knife radiosurgery is critical, as it must balance local control with the risk of radiation toxicity. A data-driven approach that personalizes treatment could improve patient outcomes and decision-making.

Data Highlights

Key Findings

• CGH-AI achieved a C-index of 0.80 for local control prediction.
• The integrated dose recommendation engine identified doses associated with improved local control outcomes.
• Biopsy-derived markers supported the robustness of the clinical-tumor-dosimetric feature set.
• The model provides interpretable, case-specific local control probabilities.
• CGH-AI facilitates personalized decision-making and follow-up planning in recurrent GBM treatment.

Clinical Implications

The implementation of CGH-AI in clinical practice could enhance the precision of dose selection for Gamma Knife radiosurgery, ultimately improving local control rates in recurrent glioblastoma patients. This approach supports a more individualized treatment strategy, aligning with contemporary standards in neuro-oncology.

Conclusion

CGH-AI represents a significant advancement in the integration of artificial intelligence into clinical workflows for recurrent glioblastoma, offering a promising tool for personalized treatment planning and outcome prediction.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Journal of Neuro-Oncology, 2025 -- Evaluating the Role of ChatGPT-4 as a Support Tool for Clinical Decision-Making in Neuro-Oncology Radiotherapy: A Prospective Comparative Analysis
3. The ASCO Post, 2020 -- ASCO20 Virtual Scientific Program: Next-Generation Oncology Highlights
4. Journal of Neuro-Oncology, 2025 -- Analysis of Tumor Control and Toxicity in Benign Intracranial Tumors Treated with HyperArc Radiosurgery Using a Frameless Linac System
5. ESTRO/EANO recommendation on reirradiation of glioblastoma
6. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma - PMC
7. Gamma Knife radiosurgery for primary and recurrent glioblastoma: Systematic review and meta-analysis with target- and protocol-based stratification
8. ESTRO/EANO recommendation on reirradiation of glioblastoma
9. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma - PMC
10. Gamma Knife radiosurgery for primary and recurrent glioblastoma: Systematic review and meta-analysis with target- and protocol-based stratification - ScienceDirect